Drug Profile
Simmiparib
Alternative Names: SMOCL-9112Latest Information Update: 21 Apr 2022
Price :
$50
*
At a glance
- Originator Shanghai Acebright Pharmaceuticals; Shanghai Institute of Materia Medica
- Developer Shanghai Acebright Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 21 Apr 2022 Discontinued - Phase-I for Solid tumours (In the elderly, Late-stage disease, In adults) in China (PO) (Acebright pipeline, April 2022)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, In adults) in China (PO, Tablet)
- 22 Mar 2017 Chemical structure information added